Bismab and Actimab Results in Treatment of Acute Myeloid Leukemia Patients

Share Article

Actinium Pharmaceuticals announces presentation of Bismab MSKCC Phase II results and interim Actimab MSKCC Phase I results at the World RadioImmunoConjugate Summit in Washington, DC.

Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy treatment of advanced cancers, announced today that an oral presentation on Bismuth 213-Lintuzumab (Bismab-A) and Actinium 225-Lintuzumab (Actimab-A) will be given at the World RadioImmuunoConjugate Summit to be held January 31, 2012 – February 2, 2012 at the Washington Marriott Hotel in Washington DC. Bismab-A and Actimab-A are alpha particle emitters labeled to a monoclonal antibody for treatment of Acute Myeloid Leukemia (AML). Alpha particle emitters can be labeled to a variety of antibodies thus allowing a potent but comparatively safe treatment of a number of hematologic and metastatic solid cancers.

Clinical Case Study: Alpha-Particle Immunotherapy for Acute Myeloid Leukemia with Bismuth-213 and Actinium-225
Presented by Principal Investigator Dr Joseph Jurcic, Associate Professor, Memorial Sloan Kettering Cancer Center
Wednesday, February 1, 2012, 09:30 – 10:00 AM EST
For more details on the congress, please visit the official congress web site:
http://www.radioimmunoconjugates.com

Key findings that will be presented include:

  • Bismuth 213-lintuzumab has antileukemic activity and can produce remissions after cytoreduction
  • Actinium 225 labeled immunoconjugates kill cancer cells at doses 1,000 times lower than 213Bi analogues
  • Therapy with Actinium 225-lintuzumab, a targeted α-particle generator, is safe and has antileukemic activity

About Actinium Pharmaceuticals
Actinium Pharmaceuticals is an oncology focused biotechnology company. The Company’s Alpha Particle Immunotherapy Technology (APIT) couples monoclonal antibodies (mAbs) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular Actinium 225 and Bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. Alpha emitters are the most powerful killing agents in existence, with a single atom capable of destroying a cancer cell. At the same time, they do not damage surrounding healthy tissues. API’s technology and products are covered by an extensive intellectual property estate of 68 patents - 17 U.S. and 51 International. (Source: http://www.actiniumpharmaceuticals.com)

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For more information, contact:
Dragan Cicic, M.D., MBA
President and CEO
Actinium Pharmaceuticals, Inc.
Tel: 973-344-6500
E-Mail: dcicic(at)actiniumpharmaceuticals(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dragan Cicic
dcicic@actiniumpharmaceuticals.com
718 369 7089
Email >
Visit website